Teva Pharmaceutical Industries (TEVA) FY2023 results: revenue $15.8 billion, up 6.2% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $15.8 billion for fiscal 2023, the year ended 31 December 2023, up 6.2% on the year before. Net income was -$559 million, and diluted earnings per share $-0.50. The figures are the company's own, from the 10-K it filed with the SEC on 12 February 2024.
Revenue
$15.8 billion
+6.2% on the year
FY2016FY2023
Operating margin
2.7%
-14.7% a year earlier
FY2016FY2023
Net income
-$559 million
FY2016FY2023
Diluted EPS
-$0.50
FY2016FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
1,368
1,590
798
-14.0%
Capital expenditure
526
548
562
-4.0%
Free cash flow
842
1,042
236
-19.2%
Free cash flow margin
5.3%
7.0%
1.5%
Cash from investing
968
656
1,523
+47.6%
Cash from financing
-1,913
-1,487
-2,172
Depreciation and amortisation
1,153
1,308
1,330
-11.9%
Share-based compensation
121
124
119
-2.4%
Diluted shares, weighted
1,119m
1,110m
1,107m
+0.8%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
7,506
7,804
10,278
-3.8%
Non-controlling interest
620
794
966
-21.9%
Redeemable equity
0.0
n/a
n/a
Debt
19,833
21,212
23,043
-6.5%
Operating lease liabilities
320
349
416
-8.3%
Other liabilities
15,200
13,847
12,963
+9.8%
Total liabilities and equity
43,479
44,006
47,666
-1.2%
Fixed assets
5,750
5,739
5,982
+0.2%
Goodwill
17,177
17,177
17,633
0.0%
Intangible assets
5,387
6,270
7,466
-14.1%
Cash and equivalents
3,226
2,801
2,165
+15.2%
Receivables
3,408
3,696
4,529
-7.8%
Inventory
4,021
3,833
3,818
+4.9%
Other assets
4,510
4,490
6,073
+0.4%
Total assets
43,479
44,006
47,666
-1.2%
10-K for the year ended 31 December 2023, filed 12 February 2024: the filing.